The outlook of companies tied to blockbuster drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the loss of exclusivity in key regions has introduced significant risk . Investors are now assessing the consequences of lower-cost alter